European Journal of Cancer
Volume 46, Issue 5 , Pages 859-862 , March 2010

Amplification of epidermal growth factor receptor gene in renal cell carcinoma

  • Iman El-Hariry

      Affiliations

    • Oncology Business Unit, GlaxoSmithKline, London UB11 1BT, United Kingdom
    • ,
  • Thomas Powles

      Affiliations

    • Department of Medical Oncology, St Bartholomew’s Hospital, London EC1A7BE, United Kingdom
    • ,
  • Mike R. Lau

      Affiliations

    • Oncology Business Unit, GlaxoSmithKline, London UB11 1BT, United Kingdom
    • ,
  • Cora N. Sternberg

      Affiliations

    • Department of Medical Oncology, San Camillo Forlanini Hospital, Rome 00152, Italy
    • ,
  • Alain Ravaud

      Affiliations

    • Department of Medical Oncology, CHU Bordeaux, 33075 Bordeaux, France
    • ,
  • Hans von der Maase

      Affiliations

    • Department of Oncology, Copenhagen University Hospital, 2100 Copenhagen, Denmark
    • ,
  • Niko Zantl

      Affiliations

    • Department of Urology and Paediatric Urology, Klinikum Konstanz, 78464 Konstanz, Germany
    • ,
  • Peter Harper

      Affiliations

    • Department of Medical Oncology, Guy’s and St Thomas’ Hospitals, London SE1 9RT, United Kingdom
    • ,
  • Frédéric Rolland

      Affiliations

    • Medical Oncology, Centre René Gauducheau, 44800 Saint Herblain, France
    • ,
  • Bruno Audhuy

      Affiliations

    • Department of Oncology-Hematology, Hôpital Pasteur, 68024 Colmar, France
    • ,
  • Friederike Barthel

      Affiliations

    • Oncology Business Unit, GlaxoSmithKline, London UB11 1BT, United Kingdom
    • ,
  • Jean-Pascal Machiels

      Affiliations

    • Department of Medical Oncology, Université catholique de Louvain, 1200 Brussels, Belgium
    • ,
  • Pina Patel

      Affiliations

    • Academic Unit of Clinical Oncology, University of Nottingham, Nottingham NG5 1PB, United Kingdom
    • ,
  • Ernst-Dietrick Kreuser

      Affiliations

    • Klinik für Internistische Onkologie und Hämatologie, Krankenhaus Barmherzige Brüder, 93049 Regensburg, Germany
    • ,
  • Robert E. Hawkins

      Affiliations

    • Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    • Corresponding Author InformationCorresponding author: Tel.: +44 161 446 3208; fax: +44 161 446 3269.

Received 23 August 2009 ,Revised 11 January 2010 ,Accepted 14 January 2010.

References 

  1. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–2540
  2. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006;24(35):5593–5600
  3. Atkins DJ, Gingert C, Justenhoven C, et al. Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas. Virchows Arch. 2005;447(3):634–642
  4. Escudier B. Anti-VEGF therapy for renal cell carcinoma. Clin Adv Hematol Oncol. 2007;5(7):530–531
  5. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [see comment]. Lancet. 2007;370(9605):2103–2111
  6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [see comment]. N Engl J Med. 2007;356(2):115–124
  7. Smith K, Gunaratnam L, Morley M, et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL−/− renal cancer. Cancer Res. 2005;65(12):5221–5230
  8. Stumm G, Eberwein S, Rostock-Wolf S, et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer. 1996;69(1):17–22
  9. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res. 2004;10(23):7812–7819
  10. Ravaud A, Hawkins R, Gardner JP, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol. 2008;26(14):2285–2291
  11. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization—why, when, and how?. Clin Cancer Res. 2006;12(14 pt 2):4409s–4415s
  12. Hirsch FR, Varella-Garcia M, McCoy J, et al. Southwest Oncology, G. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study [see comment]. J Clin Oncol. 2005;23(28):6838–6845
  13. Moch H, Sauter G, Gasser TC, et al. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol. 1998;184(4):424–429
  14. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007;18(4):752–760
  15. Jeon YK, Sung S-W, Chung J-H, et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung cancer. 2006;54(3):387–398
  16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [see comment]. N Engl J Med. 2004;350(21):2129–2139
  17. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [see comment]. Science. 2004;304(5676):1497–1500
  18. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68(7):2106–2111
  19. Sakaeda T, Okamura N, Gotoh A, et al. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res. 2005;22(10):1757–1761

PII: S0959-8049(10)00030-4

doi: 10.1016/j.ejca.2010.01.011

European Journal of Cancer
Volume 46, Issue 5 , Pages 859-862 , March 2010

Article Tools

* Image Usage & Resolution